• Castle Biosciences received New York State Department of Health assay clearance for its AdvanceAD-Tx test for moderate-to-severe atopic dermatitis.
• The non-invasive gene expression test guides systemic therapy selection for patients aged 12 or older, classifying likely response to JAK inhibitors versus Th2-targeted biologics.
• The decision expands access in New York, a state that formally reviews laboratory-developed tests before patient use.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Castle Biosciences Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: DA04254) on July 14, 2026, and is solely responsible for the information contained therein.